| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 5.29 Billion | USD 9.41 Billion | 6.62% | 2023 |
This report is based on in-depth qualitative and quantitative analyses of the global Genomic Biomarkers market. Zion Market Research has collected and analyzed key data belong to the global Genomic Biomarkers market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.
The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.
Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Genomic Biomarkers across the world has been calculated through primary and secondary research.
Zion Market Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc.
For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Genomic Biomarkers industry. Primary research makes up the major source of data collection and validation.
Primary Research
We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:
Participants who typically participate in such a process include, but are not limited to:
Key opinion leaders specializing in different areas corresponding to different industry verticals
Secondary Research
Secondary research sources that are typically referred to include, but are not limited to:
News articles, press releases, and webcasts specific to companies operating in the market
Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Genomic Biomarkers market.
Models
Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:
FrequentlyAsked Questions
The global Genomic Biomarkers Market was valued at US$ 5.29 Billion in 2023.
The global Genomic Biomarkers Market is expected to reach US$ 9.41 Billion by 2032 at a CAGR of about 6.62% from 2024 to 2032.
Some of the key factors driving the global Genomic Biomarkers Market growth are growing prevalence of life-threatening diseases such as cancer, cardiovascular diseases and neurological disorders across the globe.
North America is anticipated to remain the leading region over the forecast period followed by Europe. Demand for genomic biomarkers was highest in North America especially in the U.S. Asia Pacific is expected to be the highest growing region in genomic biomarkers market during the forecast period. Moreover, the Middle East and Africa and Latin America are also expected to show moderate growth for this market in the years to come.
Some of the major players of global Genomic Biomarkers market Thermo Fisher Scientific, Roche Diagnostics, Myriad Genetics, QIAGEN, Bio-Rad Laboratories, US Biomarkers Inc., Almac Group and Epigenomics AG among others.
HappyClients